Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Alzheimer disease (AD) is the most common form of neurodegenerative disease, estimated
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …
Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man
We characterized the world's second case with ascertained extreme resilience to autosomal
dominant Alzheimer's disease (ADAD). Side-by-side comparisons of this male case and the …
dominant Alzheimer's disease (ADAD). Side-by-side comparisons of this male case and the …
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases
R Fernández-Calle, SC Konings… - Molecular …, 2022 - Springer
ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …
Biomarker modeling of Alzheimer's disease using PET-based Braak staging
Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging
systems. Using the topographical information from [18F] MK6240 tau positron-emission …
systems. Using the topographical information from [18F] MK6240 tau positron-emission …
Develo** the ATX (N) classification for use across the Alzheimer disease continuum
Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …
Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid …
Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …
understanding of the timing of disease-related changes in tau. We quantified the …